Another vaccine has been approved in the war against the corona epidemic. Bharat Biotech’s nasal Covid-19 vaccine gets DCGI's nod for emergency use.This will be the first Neel Vaccine of the country.
New Delhi: Another vaccine has been approved in the war against the corona epidemic. On Tuesday, India’s first intranasal Covid vaccine by Bharat Biotech received DCGI approval for emergency use. Mansukh Mandaviya said the regulator has approved the vaccine for restricted use in emergency situations for primary immunization of people aged 18 years and above. Lauding the achievement, Health Minister Dr Mansukh Mandaviya said, it is a ‘Big Boost to India’s Fight Against COVID-19.
Minister of Health and Family Welfare Mandaviya tweeted, Big Boost to India’s Fight Against COVID-19! Bharat Biotech’s ChAd36-SARS-CoV-S COVID-19 (Chimpanzee Adenovirus Vectored) recombinant nasal vaccine approved by @CDSCO_INDIA_INF for primary immunization against COVID-19 in 18+ age group for restricted use in emergency situation.
Big Boost to India's Fight Against COVID-19!
Bharat Biotech's ChAd36-SARS-CoV-S COVID-19 (Chimpanzee Adenovirus Vectored) recombinant nasal vaccine approved by @CDSCO_INDIA_INF for primary immunization against COVID-19 in 18+ age group for restricted use in emergency situation.
— Dr Mansukh Mandaviya (@mansukhmandviya) September 6, 2022
Also Read :- PM Modi's jam-packed trip to Himachal Pradesh on October 5; set to inaugurate AIIMS in Bilaspur (HP) and celebrate Dussehra festivities in Kullu
He said this step will further strengthen “our collective fight” against the pandemic.
Intranasal Covid vaccine benefits: 1. The nasal route has excellent potential for vaccination due to the organized immune systems of the nasal mucosa. 2. Non-invasive, Needle-free. 3. Ease of administration – does not require trained health care workers. Elimination of needle-associated risks (injuries and infections). 4. High compliance (Ideally suits for children’s and adults).5. Scalable manufacturing – able to meet global demand.
Bharat Biotech had completed the test of the third phase and booster dose for its intranasal (intranasal) covid-19 Vaccine (COVID-19 vaccine). After which India Biotech (Bharat Biotech) had said that the intranacle has two different tests for the covid vaccine, as a first dose and second booster dose. It has proven to be safe, well-tolerated and immunogenic in subjects in controlled trials, BBIL said in a statement.
The data from both Phase III human clinical trials have been submitted for approval to national regulatory authorities, the company said.
“If approved, this intranasal vaccine will make it easier to deploy in mass immunisation campaigns with an easy to administer formulation and delivery device. Vectored vaccines also enable faster development of targeted vaccines in response to emerging variants of concern,” Bharat Biotech joint managing director Suchhitra K Ella said.
